Pharmaceuticals, Biotechnology and Life Sciences
Allergan and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation have entered into an agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.
As the medical market grows, the US Food and Drug Administration FDA has published a neat piece about biosimilars. Recently, FDA has approved a second biosimilar product—Inflectra (Infliximab-dyyb), a biosimilar to Remicade (infliximab)—and expects to approve other biosimilars in the future.
Primary Health Properties PLC, a UK-based investor in modern primary healthcare facilities, has appointed Geraldine Kennell and Nick Wiles to the Board as independent non-executive Directors.
TALTZ was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.
The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
drugmaker Sanofi has poached one of AstraZeneca’s top scientists to be its new research head in another high-profile departure for the British drugmaker.
AstraZeneca on Wednesday announced the results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90 mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA)
Drugmaker Valeant Pharmaceuticals International Inc said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business.
Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases, has provided a summary review of its 2015 performance.